Successful treatment with clarithromycin and/or tacrolimus for two patients with polymyalgia rheumatica

Masashi Ohe¹,*, Haruki Shida¹, Tetsuya Horita¹, Kenji Oku²

¹Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo Japan; ²Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo Japan.

Summary

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease in the elderly. Glucocorticoids (GCs) remain the mainstay of treatment. GC therapy usually dramatically improves the clinical picture, but approximately one-third of patients experience disease recurrence when the dose is reduced. Moreover, long-term use of GCs causes adverse reactions. Macrolide antibiotics have anti-inflammatory action. Several recent studies have reported the successful treatment of rheumatoid arthritis (RA) and PMR treated using clarithromycin (CAM), a macrolide, because of its anti-inflammatory action. Tacrolimus (TAC) has been indicated as a treatment for RA in patients who fail to respond to methotrexate. Recently, a case of RA was successfully treated using CAM and TAC according to one report. Reported here are two cases of PMR treated using CAM and/or TAC. Case 1: A 73-year-old man suffering from PMR was successfully treated with prednisolone (PSL) and CAM. Because his muscle pain disappeared, CAM was discontinued. However, the pain returned after that discontinuation, so CAM was successfully administered again. Case 2: An 83-year-old man suffering from PMR was successfully treated with PSL and CAM. Because muscle pain disappeared, the CAM dosage was halved. The pain returned after the dosage was reduced, so the CAM dosage was successfully resumed and the PSL dosage was reduced. When the PSL dosage was reduced, muscle pain recurred. Because the PSL and CAM dosages were not successfully increased, TAC was also administered and was found to be effective at treating muscle pain. These two cases suggest that CAM and/or TAC are effective at treating PMR.

Keywords: Polymyalgia rheumatica, clarithromycin, tacrolimus

1. Introduction

Macrolide antibiotics (MACs) such as clarithromycin (CAM) have anti-inflammatory action as well as antibacterial activity. Several recent studies reported the successful treatment of rheumatoid arthritis (RA) (1) and polymyalgia rheumatica (PMR) through use of CAM as an anti-inflammatory drug (2). A recent study has indicated that tacrolimus (TAC), a Japanese domestic disease-modifying antirheumatic drug, is a treatment for active RA patients who fail to respond

to methotrexate (3). Recently, a case of RA was successfully treated with CAM and TAC (4). Reported here are a case of PMR treated with CAM and a case of PMR treated with CAM and TAC.

2. Case Reports

2.1. Case 1

A 73-year-old man presented with subacute onset of severe muscle pain in his neck, both shoulders, his lower back, and both thighs. Muscle tenderness was noted in all of the areas in question. However, swelling and deformity of joints were not noted. Laboratory results were a white blood cell count (WBC) of 9,090 cells/µL (normal range, 4,000 to 9,800 /µL), a C-reactive protein (CRP) level of 7.14 mg/dL (normal value, < 0.3
mg/dL), an erythrocyte sedimentation rate of 95 mm/h (normal range, 1 to 10 mm/h), a rheumatoid factor concentration of < 15 IU/mL (normal value, < 15 IU/mL), and an antinuclear antibody (ANA) titer of 40× (normal value, < 40×). Tests for myeloperoxidase and proteinase-3 antineutrophil cytoplasmic antibodies were negative. Ultimately, the patient was diagnosed with PMR and treated with prednisolone (PSL) (15 mg/day). According to a previous report (2) CAM has anti-inflammatory action, so the current patient was also treated with CAM (400 mg/day). After 1 week of this treatment, muscle pain disappeared, and CRP decreased to 0.67 mg/dL. The trough level of TAC was 3.3 ng/mL. The PSL dosage could not be decreased any further for fear of recurrent muscle pain, so TAC (0.5 mg/day) and CAM (400 mg/day) was administered. Four weeks after starting this treatment, slight muscle pain developed but this was tolerated by the patient. Eight weeks after starting this treatment, muscle pain worsened, and CRP increased to 12.97 mg/dL (second relapse). The PSL dosage was increased to 10 mg/day and the CAM dosage was increased to 400 mg/day. The trough level of TAC was 3.3 ng/mL. The PSL dosage was gradually decreased to 4 mg/day, and CRP remained at 0.30 mg/mL while the patient received PSL (10 mg/day) and CAM (400 mg/day). The PSL dosage could not be decreased any further for fear of recurrent muscle pain, so TAC (0.5 mg/day) was also administered. One week after the addition of TAC treatment, CRP decreased to 0.55 mg/dL. The trough level of TAC was 3.3 ng/mL. The PSL dosage was gradually decreased to 4 mg/day, and CRP remained at 0.30 mg/mL without recurrent muscle pain.

3. Discussion

Glucocorticoids (GCs) are the mainstay of PMR treatment. GC therapy usually dramatically improves the clinical picture within a few days, but approximately one-third of patients experience disease recurrence when the dose is reduced. Long-term use of GC causes adverse reactions in up to 60% patients.

MACs have anti-inflammatory action as well as antibacterial activity. MACs exhibit anti-inflammatory action by affecting several pathways of the inflammatory process, such as the production of proinflammatory cytokines. In fact, CAM inhibits the production of interleukin-6 (IL-6) (5), which is associated with the clinical features of RA. Similarly, TAC has been reported to suppress the production of IL-6 (6). Serum IL-6 levels are reported to increase and are closely associated with disease activity in PMR (7), so the efficacy of treatment with CAM and/or TAC in the current cases might be due to the anti-inflammatory action of CAM and/or TAC with regard to the suppression of IL-6 production. In Case 1, CAM was effective in treating both relapses. In Case 2, however, CAM was effective in treating the first relapse but not in treating the second relapse. This necessitated
Because only two cases have been reported here, more research is necessary before this treatment with CAM and/or TAC can be adopted on a wider basis.

References


(Received July 19, 2017; Revised August 6, 2017; Accepted August 12, 2017)